Published in Hypertension on February 03, 2014
Response to hypertension guidelines: political correctness trumping expertise? Hypertension (2014) 0.75
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol (2008) 7.04
Obesity paradox in patients with hypertension and coronary artery disease. Am J Med (2007) 5.61
Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet (2008) 5.05
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ (2013) 3.98
Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation (2011) 3.81
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA (2004) 3.20
A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol (2007) 3.07
Atrial fibrillation and obesity--results of a meta-analysis. Am Heart J (2007) 2.86
Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol (2010) 2.77
Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians' Desk Reference. Am J Med (2010) 2.33
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J (2010) 2.32
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 2.16
Visceral angioedema due to angiotensin-converting enzyme inhibitor therapy. Cleve Clin J Med (2011) 2.09
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study. Hypertension (2004) 1.90
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med (2003) 1.83
Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol (2007) 1.76
Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med (2011) 1.66
Beta-blockers for primary prevention of heart failure in patients with hypertension insights from a meta-analysis. J Am Coll Cardiol (2008) 1.52
Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol (2004) 1.52
Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens (2007) 1.51
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke (2007) 1.46
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. J Hypertens (2012) 1.45
Antihypertensive therapy and new onset diabetes. J Hypertens (2004) 1.45
Authors' reply to Laragh and Sealey. BMJ (2013) 1.40
Of millimeterology and cannibalism: comparative antihypertensive efficacy of angiotensin receptor blockers. Am Heart J (2003) 1.39
The renin-angiotensin systems: evolving pharmacological perspectives for cerebroprotection. Curr Pharm Des (2005) 1.39
Trials on the effect of cardiac resynchronization on arterial blood pressure in patients with heart failure. Am J Cardiol (2010) 1.38
Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke (2006) 1.33
Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol (2006) 1.32
Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) (2012) 1.29
Left ventricular geometry and mortality in patients >70 years of age with normal ejection fraction. Am J Cardiol (2006) 1.26
Beyond salt: lifestyle modifications and blood pressure. Eur Heart J (2011) 1.24
Salt and hypertension: is salt dietary reduction worth the effort? Am J Med (2012) 1.22
Disparate effects of left ventricular geometry and obesity on mortality in patients with preserved left ventricular ejection fraction. Am J Cardiol (2007) 1.21
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy. Am J Med (2010) 1.17
Is there an association between hypertension and cancer mortality? Am J Med (2002) 1.15
Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med (2012) 1.14
Hypertension management 2011: optimal combination therapy. Eur Heart J (2011) 1.13
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol (2006) 1.12
Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J (2009) 1.09
Optimal renin-angiotensin system blockade-wishful thinking? Nat Rev Cardiol (2013) 1.08
International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol (2013) 1.05
Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens (2011) 1.01
Compliance and fixed-dose combination therapy. Curr Hypertens Rep (2007) 1.00
Antihypertensive effects of statins: a meta-analysis of prospective controlled studies. J Clin Hypertens (Greenwich) (2013) 0.99
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy. Hypertension (2009) 0.98
Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens (2009) 0.96
Takotsubo-like cardiomyopathy in pheochromocytoma. Int J Cardiol (2011) 0.96
Calcium antagonists. Prog Cardiovasc Dis (2004) 0.95
Angiotensin-converting enzyme inhibitors and angioedema: estimating the risk. Hypertension (2008) 0.92
Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark? Circulation (2009) 0.92
Gun ownership and firearm-related deaths. Am J Med (2013) 0.91
ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point. Am J Med (2013) 0.90
Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J (2006) 0.90
Hypertension and diabetes. Adv Cardiol (2008) 0.89
Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart (2012) 0.88
The j-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep (2012) 0.88
Hypertension in the elderly: some practical considerations. Cleve Clin J Med (2012) 0.88
Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol (2012) 0.86
Discrepancies between office and ambulatory blood pressure: clinical implications. Am J Med (2009) 0.86
Treatment of hypertension in the elderly. N Engl J Med (2008) 0.86
Characteristics of contemporary patients with hypertension and coronary artery disease. Clin Cardiol (2004) 0.85
Are fixed-dose combination antihypertensives suitable as first-line therapy? Curr Med Res Opin (2012) 0.85
Management of blood pressure in patients with diabetes. Am J Hypertens (2011) 0.85
TIMPs, MMPs and cardiovascular disease. Eur Heart J (2004) 0.84
Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]). Am J Cardiol (2010) 0.84
Beta-blockers as first-line antihypertensive therapy the crumbling continues. J Am Coll Cardiol (2009) 0.83
Obesity, weight reduction and survival in heart failure. J Am Coll Cardiol (2002) 0.83
Long-term safety of antihypertensive therapy. Prog Cardiovasc Dis (2006) 0.83
Erythrocyte membrane properties in patients with essential hypertension. Cell Biochem Biophys (2013) 0.83
Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol (2013) 0.82
Blood pressure and diabetes: vicious twins. Heart (2013) 0.82
Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med (2009) 0.81
Secondary prevention after ischemic stroke. N Engl J Med (2012) 0.81
Dual RAS blockade-unresolved controversy? Nat Rev Nephrol (2013) 0.81
Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev (2015) 0.81
Carcinogenicity of antihypertensive therapy. Curr Hypertens Rep (2002) 0.80
Beta-blocker therapy and depression. JAMA (2002) 0.80
Are calcium antagonists beneficial in diabetic patients with hypertension? Am J Med (2004) 0.80
Paradoxical hypertension with cardiac tamponade. Am J Cardiol (2012) 0.80
Effects of renin-angiotensin system blockade on mortality and hospitalization in heart failure with preserved ejection fraction. Heart Fail Rev (2013) 0.80
Treatment-resistant hypertension: another Cinderella story. Eur Heart J (2013) 0.79
Appropriateness of statins in patients aged ≥80 years and comparison to other age groups. Am J Cardiol (2012) 0.79
A novel pathway for the management of hypertension for hospitalized patients. Crit Pathw Cardiol (2007) 0.79
"One" cup of coffee and nuclear SPECT to go. J Am Coll Cardiol (2007) 0.79
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. J Clin Hypertens (Greenwich) (2007) 0.79
Aspirin: a novel antihypertensive drug? Or two birds with one stone? J Am Coll Cardiol (2005) 0.79
Resting heart rate and cardiovascular disease: the beta-blocker-hypertension paradox. J Am Coll Cardiol (2008) 0.78
Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med (2008) 0.78
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr (2008) 0.78
How useful are beta-blockers in cardiovascular disease? Anadolu Kardiyol Derg (2006) 0.78
Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors. JAMA (2003) 0.78